Jiangsu Zhongbang Pharmaceutical Co.,Ltd.

Wholly owned by the state-run large-scaled Red Sun Group Corporation, Jiangsu Zhongbang Pharmacy Co., Ltd. has a total investment of RMB200 million, and takes up a land of 200,000 m2. It is a hi-tech enterprise mainly developing and producing L-ephedrine serial products, heart and brain blood vessel disease, infection, respiration system, metabolism and incretion. With the technology base of Nanjing Red Sun Engineering Technology Center and Nanjing Red Sun Biological Pharmacy Engineering Technology Center, the company cooperates with other strong parties as China Pharmacy University, Dalian Institute of Physics and Chemistry, Jiangsu Province Institute of Material and Medicament and Metoblex Company in USA. It constantly promotes the strength in the raw material synthesizing pyridine ramification, R&D of new medicine, and innovation of formulations. Meanwhile the company carries out end-reaching sales business of medicines with the support of the strong medicine operating network, sales foundation, and clinical teams of Jiangsu Haibang Pharmacy Co., Ltd.

The company has completed the building of synthesizing workshops for raw material medicine, refine-dryness-package, and solid formulations, all meeting the GMP standard.. Presently 2 second category new medicines have entered the stage of clinical trial, and 1 first category new medicine, 2 second category new medicines and 3 fourth category new medicines have entered the stage of pre-clinical study. 7 raw material medicines and pharmaceutical intermediates are now for sale in the market. With a perfect and rigorous quality safeguard system, the company guarantees production quality and provides a well-equipped off-sales service system.

With its competitive technology advantage, strong capital, excellent R&D, outstanding quality, first class production and technology, the company aims to become a renowned large-scale pharmacy company that has its self-owned intellectual property, a rational production structure, and strong core competitiveness, and a resources combination and transforming body with the integration of R&D, production, and sales of medicines.